# Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/afatinib-versus-cisplatin-plus-gemcitabine-for-first-line-treatment-of-asian/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Yi‐Long Wu,Caicun Zhou,Chengping Hu,Jifeng Feng,Shun Lü,Yunchao Huang,Wěi Li,Mei Hou,Jian Hua Shi,Kye Young Lee,Chong‐Rui Xu,Dan Massey,Miyoung Kim,Yang Shi,Sarayut Lucien Geater |
| Citations | 1,984 |
| DOI | 10.1016/s1470-2045(13)70604-1 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2171139285 |
| PMID | 24439929 |
| Type | article |
| Year | 2014 |

## Paper authors

- [Yi‐Long Wu](https://scholariq.org/researchers/yi-long-wu/)
- [Chong‐Rui Xu](https://scholariq.org/researchers/chong-rui-xu/)

## Paper journal

- [The Lancet Oncology](https://scholariq.org/journals/the-lancet-oncology/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.